The Geron Corporation (NASDAQ:GERN) On Mar. 12 announced that the company has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for imetelstat has been placed on full clinical hold, affecting all ongoing company-sponsored clinical trials. A full clinical hold is an order that the FDA issues to a trial sponsor to suspend an ongoing clinical trial or delay a proposed trial. Geron Corporation (NASDAQ:GERN) shares after opening at $2.15 moved to $2.38 on last trade day and at the end of the day closed at $2.24. Company price to sales ratio in past twelve months was calculated as 169.04 and price to cash ratio as 4.34. Geron Corporation (NASDAQ:GERN) showed a positive weekly performance of 25.14%.
The sudden resignation of Synta Pharmaceuticals Corp (NASDAQ:SNTA) CEO as well as below par financial results seems to be arousing concerns with analysts at various research equity firms who have consequently downgraded the company’s rating in the market. Analysts at MLV &Co have cut their share price target on Synta Pharmaceuticals stock from a high of $10 to $6, ina research note issued to investors on March 13. They currently have a buy rating on the company’sstock which indicates 36.99% potential upside on the current share price. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares advanced 9.47% in last trading session and ended the day on $5.20. SNTA return on equity ratio is recorded as -231.70% and its return on assets is -112.90%. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) yearly performance is -37.80%.
Agenus Inc (NASDAQ:AGEN) declared that GlaxoSmithKline’s (NYSE: GSK) MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii cancer immunotherapeutic trial in non-small cell lung cancer patients, which contains Agenus’QS-21 Stimulon(R) adjuvant, did not meet its first or second co-primary endpoint.Agenus Inc (NASDAQ:AGEN) shares moved down -11.63% in last trading session and was closed at $3.80, while trading in range of $3.37-$4.02. Agenus Inc (NASDAQ:AGEN) year to date performance is 43.94%.
The Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) On Mar. 10 announced initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors. The study is still ongoing and the maximal tolerated dose (MTD) has not yet been achieved. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) weekly performance is 7.32%. On last trading day company shares ended up $1.32. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) distance from 50-day simple moving average is 14.80%. Analysts mean target price for the company is $2.23.